MediWound (NASDAQ:MDWD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of MediWound (NASDAQ:MDWD) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

MDWD has been the subject of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a report on Wednesday, October 8th. Zacks Research raised shares of MediWound from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target (up previously from $31.00) on shares of MediWound in a report on Friday. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $33.50.

MediWound Trading Up 6.2%

Shares of MediWound stock opened at $18.12 on Friday. The business’s fifty day simple moving average is $18.04 and its 200 day simple moving average is $18.85. MediWound has a 12 month low of $14.14 and a 12 month high of $22.50. The firm has a market capitalization of $200.90 million, a P/E ratio of -6.86 and a beta of 0.22.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Thursday, November 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.57. The firm had revenue of $5.43 million during the quarter, compared to the consensus estimate of $6.56 million. MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%. Analysts predict that MediWound will post -2.66 EPS for the current fiscal year.

Institutional Investors Weigh In On MediWound

Several institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets grew its position in shares of MediWound by 90.4% in the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 723 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 649 shares during the period. Corebridge Financial Inc. grew its holdings in MediWound by 17.1% during the 1st quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 665 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 999 shares during the period. Finally, Deutsche Bank AG lifted its holdings in shares of MediWound by 2,255.2% in the first quarter. Deutsche Bank AG now owns 6,312 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 6,044 shares in the last quarter. Hedge funds and other institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.